Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hippocampal Sclerosis (HS) leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.
Hippocampal sclerosis (HS) refers to neuronal cell loss and astrocytosis in subiculum and cornu ammonis subfields of the hippocampal formation unrelated to Alzheimer's disease pathology. In contrast to HS that affects younger adults with epilepsy, older individuals with HS have significant ante-mortem cognitive dysfunction but no epilepsy. Neuropathological studies demonstrated three main types of HS associated with aging: (a) HS-Ageing to refer to the disease with HS pathology in ageing individuals, observed in more than 10% of subjects aged over 85 years; (b) HS observed in the behavioural variant of frontotemporal dementia (bvFTD), HS being more frequent in tau-negative pathology, especially in FTLD-TDP. bvFTD patients may manifest severe episodic memory impairment and hippocampal atrophy; (c) HS associated with cortical or subcortical cerebral microinfarcts, which are invisible on conventional MRI. Cerebral microinfarcts are observed in 33% of elderly over 85 years in post-mortem studies.
HS leads to anterograde amnesia mimicking early Alzheimer's disease (AD) (so called HSA-nonAD). Recent studies showed that (a) the deficit of episodic memory as well as the level of hippocampal atrophy in bvFTD may be of similar severity to that observed in AD, even at initial presentation, leading to misdiagnosis in 22% of cases with post mortem diagnosis; (b) amnesia with HS due to microvascular lesion and microinfarcts can also cause impairment of episodic memory mimicking AD, without subcortical cognitive profile. Because these diseases involve distinct pathophysiological processes, they require different specific care and treatment. In consequence, it is very important to improve our knowledge about HS in order to identify its mechanism and improve the diagnosis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with Hippocampal sclerosis non AD | Other | Patients with Hippocampal sclerosis non AD (n=40) |
|
| Patients with Alhzeimer's Disase | Other | Patients with Alhzeimer's Disase (n=40) |
|
| Patients with DLFT | Other | Patients with DLFT (n=20) |
|
| Patients with CBD/PSP | Other | Patients with CBD/PSP (n=20) |
|
| Normal controls | Other |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neurological examinations | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| 7 tesla MRI. | Structural morphometric analysisze of hippocampal and Papez circuit sub-regions, and detection of microinfarcts/microbleeds by 7 tesla MRI. | up to Month 18 |
| Measure | Description | Time Frame |
|---|---|---|
| 3T MRI | Morphometry of hippocampus by 3T MRI | Baseline |
| 3T MRI | Morphometry of hippocampus by 3T MRI | Month 12 |
Not provided
Inclusion Criteria:
General inclusion criteria
Patients with Hippocampal sclerosis non AD (n=40)
Clinical criteria :
Biological criteria : Absence of Profile suggestive of AD on the study of the biomarkers of the CSF (IATI ratio > 0.8)
Patients with Alheimer's Disase (n=40)
Clinical criteria :
Biological criteria : CSF biomarkers suggestive of AD defined on CSF.
Patients with DLFT (n=20) :
Clinical criteria :
Patients with CBD/PSP (n=20) (Armstrong et al., 2013)
Corticobasal syndrome :
Progressive supranuclear palsy syndrome :
Normal controls (n=20):
Absence of known psychiatric disorder Score on the Folstein Mini Mental Status (MMSE > or = 27) Normal neuropsychological assessment for the age and the educational level
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marie SARAZIN, MD, PhD | Centre Hospitalier Sainte-Anne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Neurologie de la mémoire et du langage, Service de Neurologie, Centre Hospitalier Sainte-Anne | Paris | 75014 | France |
Not provided
| ID | Term |
|---|---|
| D000647 | Amnesia |
| D000092223 | Hippocampal Sclerosis |
| ID | Term |
|---|---|
| D008569 | Memory Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012149 | Restraint, Physical |
| ID | Term |
|---|---|
| D032763 | Behavior Control |
| D013812 | Therapeutics |
| D007103 | Immobilization |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Normal controls (n=20)
|
| Neuropsychological examinations | Other |
|
| Clinical examinations | Other |
|
| MRI 3T | Radiation |
|
| MRI 7T | Radiation |
|
| 3T MRI | Morphometry of hippocampus by 3T MRI | Month 24 |
| 3T MRI | White matter intensities assessed by 3T MRI | Baseline |
| 3T MRI | White matter intensities assessed by 3T MRI | Month 12 |
| 3T MRI | White matter intensities assessed by 3T MRI | Month 24 |
| 7T MRI | Volumetry of the cholinergic nucleus basalis by 7T MRI | up to Month 18 |
| CSF | CSF biomarkers | Baseline |
| Neuropsychological assessment | Neuropsychological assessment | Baseline |
| Neuropsychological assessment | Neuropsychological assessment | Month 12 |
| Neuropsychological assessment | Neuropsychological assessment | Month 24 |
| Clinical assessment | Clinical assessment | M0 |
| Clinical assessment | Clinical assessment | Month 12 |
| Clinical assessment | Clinical assessment | Month 24 |
| Genetic markers of bvFTD | Genetic markers of bvFTD | Baseline |
| Blood markers | Blood markers | Baseline |
| Plasmatic progranulin levels | Plasmatic progranulin levels | Baseline |
| Regional glucose hypometabolism | Regional glucose hypometabolism assessed by FDG-PET (if performed during clinical care). | Baseline |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D065703 | Malformations of Cortical Development, Group I |
| D054220 | Malformations of Cortical Development |
| D009421 | Nervous System Malformations |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |